Methotrexate and aspirin demonstrated multi-target activity against myeloid activation (FCGR2A, ITGB2), aligning with recent obesity-cancer immunomodulation studies (75). Here, FCGR2A is linked to obesity due to melanocortin 4 receptor deficiency.